20 June 2016
Post-market Clinical Study Evaluates Axonics Miniaturized, Rechargeable System for Overactive Bladder Patients
16 June 2016
Wilson Therapeutics AB (publ), announces the appointment of Rick Lilley as Chief Regulatory Officer. Dr Lilley will report to CEO Jonas Hansson and will join the company’s management team.
6 June 2016Axonics Sacral Neuromodulation System Receives CE Mark for the Treatment of Urinary and Fecal Dysfunction
Axonics Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, announced today that it has received a marquage de Conformité Européenne (CE Mark) for its SNM System to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention.
23 May 2016InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation
InDex Pharmaceuticals AB today announced it has been granted 1.825 million SEK from Sweden´s innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases. Of 535 applications and 84 funded projects, InDex received one of the largest grants.
18 May 2016
Wilson Therapeutics AB (publ), announces that the company's ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.